

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **FOSUN INTERNATIONAL LIMITED**

*(Incorporated in Hong Kong with limited liability under the Companies Ordinance)*

**(Stock Code: 00656)**

### **ANNOUNCEMENT PRINCIPAL FINANCIAL DATA AND INDICATORS OF FOSUN PHARMA FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2010**

Reference is made to the overseas regulatory announcement dated 27 October 2010 (the "**Announcement**") and issued by Fosun International Limited (the "**Company**") in relation to the extract of the 2010 third quarter report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**"), a subsidiary of the Company and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal financial data and indicators of Fosun Pharma for the nine months ended 30 September 2010 as set out in the Announcement:

#### **Principal Financial Data and Indicators of Fosun Pharma**

Currency: RMB

	As at the end of this reporting period	As at the end of last year	Increase/decrease as at the end of this reporting period as compared with the end of last year (%)
Total assets (yuan)	14,409,128,290.36	11,527,145,937.29	25.00
Owners' equity (or shareholders' equity) (yuan)	7,947,126,064.22	6,476,522,231.34	22.71
Equity per share attributable to shareholders of the listed company (yuan/share)	4.17	5.23	-20.27

	From the beginning of 2010 up to the end of this reporting period (January - September)		Increase/decrease as compared with the same period last year (%)
Net cash flow from operating activities (yuan)	90,765,779.34		-20.86
Net cash flow per share from operating activities (yuan/share)	0.0477		-48.56
	Reporting period (July - September)	From the beginning of 2010 up to the end of this reporting period (January - September)	Increase/decrease of this reporting period as compared with the same period last year (%)
Net profit attributable to shareholders of the listed company (yuan)	186,572,441.03	738,011,644.91	-90.04
Basic earnings per share (yuan/share)	0.10	0.39	-90.29
Basic earnings per share net of non-recurring gain or loss (yuan/share)	0.06	0.20	-8.70
Diluted earnings per share (yuan/share)	0.10	0.39	-90.29
Weighted average return on equity (%)	2.41	10.37	decreased by 32.24 percentage points
Weighted average return on equity net of non-recurring gain or loss (%)	1.59	5.34	decreased by 0.84 percentage point

Note: The full text of the 2010 third quarter report of Fosun Pharma will be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>).

By Order of the Board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

Shanghai, the PRC, 27 October 2010

*As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetang and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.*